United States Patent 6,165,497: Claim Scope, Expiration, and Nicotine Transdermal Patent Landscape

U.S. Patent 6,165,497 protects specific nicotine transdermal patch architectures that combine a sub-saturated nicotine reservoir, a nicotine-permeable rate-controlling membrane, an adhesive layer, and sustained delivery over at least eight hours. Its strongest claim concepts are the reservoir and membrane relationship, controlled nicotine flux, low thermodynamic activity, and 16-hour or longer delivery. The patent is no longer an enforceable barrier to U.S. commercial entry because its term expired in 2017.

The patent is relevant historically to nicotine patches such as Nicoderm, Habitrol, and related reservoir-based systems. It is not an active Orange Book barrier to current nicotine-replacement products.

What does U.S. Patent 6,165,497 cover?

The patent covers transdermal nicotine devices and methods using a controlled-release reservoir system. The core design contains:

A nicotine reservoir in which nicotine is dissolved in a solvent below saturation.
A membrane controlling nicotine migration from the reservoir.
An adhesive positioned between the membrane and the skin.
A delivery rate of approximately 250 to 4,000 micrograms per hour for a substantial part of the treatment period.
A treatment period of at least eight hours, with certain claims extending to at least 16 hours.

The patent is directed to a reservoir patch rather than a simple drug-in-adhesive system. A patch that places nicotine directly in the adhesive without a separate reservoir may fall outside the principal architecture of claims 1, 8, and 9, although other claims or related patents could still be relevant.

The patent’s claim structure is summarized below.

Claim	Subject matter	Principal limitation
1	Medical device	Nicotine reservoir, rate-controlling membrane, adhesive, 8-hour period, 250-4,000 μg/hr delivery
2	Device of claim 1	Reservoir thermodynamic activity no greater than 0.50
3	Device of claim 2	Adhesive has high nicotine solubility
4	Device of claim 2	At least 50% of initial nicotine loading is in the reservoir
5	Device of claim 1	Reservoir and adhesive activity between 0.20 and 0.40
6	Device of claim 1	Steady-state flux of 23 μg/cm²/hr
7	Device of claim 1	Repeats the 23 μg/cm²/hr flux limitation
8	Transdermal patch	Reservoir, occlusive backing, at least 16-hour useful flux, average flux below 200 μg/cm²/hr
9	Transdermal patch	Reservoir, occlusive backing, 8-hour period, flux between 23 and 800 μg/cm²/hr
10	Administration method	Application of the claim 8 patch to a patient
11	Administration method	Application of the claim 9 patch to a patient
12	Patch of claim 8	Steady-state flux stated as 30-120 mg/cm²/hr
13	Method of claim 10	Same flux range stated as claim 12

What are the independent claims in U.S. Patent 6,165,497?

Claims 1, 8, 9, 10, and 11 are the operative independent claims.

Claim 1: controlled-rate nicotine device

Claim 1 requires a combination of structural and functional elements:

A nicotine reservoir.
Nicotine dissolved in a solvent at a concentration below saturation.
Sufficient nicotine to provide 250-4,000 μg/hr.
A rate-controlling membrane in the migration path.
A substantially constant delivery rate during a substantial portion of the administration period.
An adhesive in the migration path between the rate-controlling element and skin.
An administration period of at least approximately eight hours.

This claim is relatively narrow because it requires both a specific multilayer arrangement and a performance result. A product designer seeking to avoid literal infringement could examine whether the product has a separate reservoir, whether a distinct membrane controls release, and whether the adhesive is in the claimed migration path.

The phrase "substantially constant" is a functional limitation. It does not require a mathematically flat release curve, but it requires a controlled rate rather than an initial burst followed by rapid decline. The phrase "substantial portion" introduces factual questions concerning the duration and magnitude of the controlled-release phase.

Claims 8 and 9: patch construction and flux

Claim 8 requires:

A nicotine reservoir layer.
A skin-facing and skin-distal side.
An occlusive backing layer covering the skin-distal side.
Enough nicotine to maintain useful flux for at least 16 hours.
Rate control producing an average transdermal flux below 200 μg/cm²/hr.

Claim 9 is broader in duration but uses a defined flux range:

At least eight hours of useful flux.
An occlusive backing layer.
A nicotine-permeable rate-controlling membrane.
Flux between 23 and 800 μg/cm²/hr.

Claims 8 and 9 are important because they claim the patch as a physical product rather than only the general device combination of claim 1. Claim 8 emphasizes long duration and an upper flux ceiling. Claim 9 emphasizes the membrane and a numerical flux window.

A patch could potentially satisfy claim 9 while avoiding claim 8 if its average flux is not below 200 μg/cm²/hr or if it cannot sustain useful delivery for 16 hours. Conversely, a patch could fall within claim 8 but outside claim 9 if its flux is below 23 μg/cm²/hr.

Claims 10 and 11: method claims

Claims 10 and 11 require applying the claimed patch to an individual. These claims do not materially expand the technical requirements of claims 8 and 9. They convert the patch limitations into treatment-method limitations.

Method claims generally require proof that the accused product is used in the claimed manner. A product manufacturer can face different infringement exposure from a method claim depending on labeling, instructions, promotional materials, and actual use.

How do the dependent claims narrow the patent scope?

The dependent claims focus on thermodynamic activity, nicotine distribution, adhesive solubility, and flux.

Thermodynamic activity limitations

Claim 2 limits the initial equilibrated thermodynamic activity of nicotine in the reservoir to no more than 0.50. Claim 5 narrows the activity range in the reservoir and adhesive layers to 0.20-0.40.

Thermodynamic activity is distinct from nicotine concentration. It reflects the chemical potential or escaping tendency of nicotine in the formulation. Two patches with the same nicotine concentration can have different activities because of differences in solvent composition, polymer structure, excipients, and adhesive chemistry.

These limitations favor formulations engineered for controlled release and reduced initial driving force. They may be difficult to establish from a product label alone. Technical testing, formulation records, and physicochemical analysis would ordinarily be required.

High-nicotine-solubility adhesive

Claim 3 requires an adhesive with high nicotine solubility. The claim does not provide a universal numerical threshold in the text supplied. That limitation would likely be interpreted in the context of the specification, comparative examples, and the role of the adhesive in maintaining nicotine transport.

A pressure-sensitive adhesive that also functions as the drug reservoir may not automatically satisfy this limitation. The adhesive must have the claimed solubility characteristic, and the product must also satisfy the incorporated limitations of claims 1 and 2.

Reservoir loading

Claim 4 requires at least 50% of the initial nicotine loading to be in the reservoir. This limitation differentiates a reservoir-dominant patch from an adhesive-dominant design.

This is a potentially useful noninfringement distinction for drug-in-adhesive products. A manufacturer could argue that most nicotine is present in the adhesive rather than in a physically separate reservoir. The result would depend on the product’s layer definitions and whether the adhesive itself constitutes the reservoir.

What technical features create the main infringement risk?

The highest-risk combination is a nicotine patch with all of the following characteristics:

A discrete nicotine reservoir layer.
A polymeric or other solvent-containing reservoir with nicotine below saturation.
An occlusive backing layer.
A distinct nicotine-permeable membrane.
A separate skin-contact adhesive.
Eight-hour or longer delivery.
A controlled nicotine flux within the claimed ranges.
A formulation with low thermodynamic activity.
At least 50% of the nicotine load in the reservoir.

A conventional reservoir patch may therefore implicate the patent’s claim concepts even if its commercial dose is described in milligrams per day rather than micrograms per hour.

The claims use both total delivery rate and area-normalized flux. Those measurements must be kept separate:

Measurement	Unit in the claims	Meaning
Total administration rate	μg/hr	Nicotine delivered by the entire patch
Transdermal flux	μg/cm²/hr	Nicotine delivered per unit patch area
Total loading	mg or percentage	Amount initially contained in the patch or a particular layer

Patch area is material. A product delivering 1 mg over 24 hours may have a total rate of approximately 41.7 μg/hr, but its flux depends on patch area and may not fall within the claimed flux ranges.

Are claims 6, 7, 12, and 13 technically consistent?

The supplied claim text contains apparent drafting or transcription problems.

Claims 6 and 7 are duplicates. Both recite a steady-state flux of 23 μg/cm²/hr. The duplication does not create two independent technical limitations. One claim may have been intended to contain a different dependency or numerical range.

Claims 12 and 13 state a steady-state flux of 30-120 mg/cm²/hr. That value is several orders of magnitude higher than the other claim ranges and is not technically consistent with ordinary nicotine transdermal delivery. The intended unit may have been μg/cm²/hr rather than mg/cm²/hr.

This issue matters for claim construction and validity analysis. A court could consider the issued patent, prosecution history, specification, and certificate or correction records when determining whether the unit is an obvious typographical error or an enforceable limitation. A literal reading of 30-120 mg/cm²/hr would describe an implausibly high flux for a nicotine patch and could create enablement, written-description, indefiniteness, or operability issues.

When did U.S. Patent 6,165,497 lose exclusivity?

U.S. Patent 6,165,497 expired in 2017 under the patent term applicable to the patent. The patent issued on December 26, 2000. The relevant term was governed by the pre-Uruguay Round Agreements Act 17-year-from-issuance framework associated with the patent’s filing history, rather than a new 20-year term calculated solely from the issue date.

The practical result is that the patent does not currently block manufacture, sale, or use of a nicotine patch in the United States. Patent expiration eliminates ordinary infringement liability for the expired claims, although it does not eliminate exposure under other active patents, trade secrets, regulatory requirements, or product-liability law.

Event	Date or status
Patent issued	December 26, 2000
Patent term	Historical U.S. patent term applicable to the patent
Expiration	2017
Current enforceability	Expired
Current Orange Book barrier	None attributable to this patent

The USPTO Patent Center and the official patent record remain the controlling sources for the specific term calculation and any recorded terminal disclaimer or adjustment.

What is the Orange Book status of U.S. Patent 6,165,497?

U.S. Patent 6,165,497 is not an operative Orange Book patent barrier for nicotine replacement products.

Nicotine replacement products have historically been marketed through prescription and over-the-counter pathways, including nicotine patches, gum, lozenges, inhalers, and nasal products. FDA’s Orange Book listing system is relevant to approved prescription products and listed patents, but an expired patent cannot prevent approval or marketing based on its former exclusivity.

Nicotine patches marketed under products such as Nicoderm CQ and Habitrol are also subject to FDA monograph and product-specific regulatory requirements. Since the United States transitioned nicotine replacement therapy toward over-the-counter availability, the competitive barrier has shifted from patent exclusivity to formulation, manufacturing, regulatory compliance, brand recognition, distribution, and consumer adherence.

Were Paragraph IV challenges likely under this patent?

A Paragraph IV challenge would not be commercially relevant today because the patent has expired. During its active term, the patent could have been relevant to an ANDA applicant seeking approval for a generic nicotine patch if the reference product and listed patents were subject to an ANDA pathway.

Paragraph IV exposure would have depended on:

Whether the patent was listed for the relevant reference product.
Whether the generic patch used a reservoir and membrane architecture.
Whether the proposed product met the claimed duration and flux ranges.
Whether the applicant certified noninfringement, invalidity, or unenforceability.
Whether the FDA product pathway treated the product as an ANDA-eligible generic rather than an OTC monograph product.

No current generic-launch strategy should treat Patent 6,165,497 as a live Paragraph IV obstacle. Any present patent review should focus on later patents, formulation patents, manufacturing processes, trademarks, and regulatory exclusivity.

How does this patent compare with other nicotine patch patent estates?

Patent 6,165,497 belongs to the earlier technical generation of nicotine transdermal systems. The broader patent landscape includes several overlapping categories.

Patent category	Typical protected subject matter	Relevance today
Reservoir-patch patents	Nicotine reservoir, membrane, backing, adhesive	Mostly expired for early products
Drug-in-adhesive patents	Nicotine dispersed directly in pressure-sensitive adhesive	Potentially relevant only if later patents remain active
Adhesive chemistry patents	Acrylate, silicone, or hybrid adhesive systems	May create formulation or manufacturing barriers
Layer and backing patents	Occlusive films, liners, skin-contact structures	Usually product-specific
Manufacturing patents	Coating, drying, lamination, pouching, and loading processes	Can remain relevant after composition patents expire
Method-of-use patents	Smoking cessation, dose escalation, or combination therapy	Limited commercial value if expired or not listed
Device and packaging patents	Patch geometry, release control, child resistance, packaging	May support secondary protection

The principal commercial distinction is between a reservoir patch and a drug-in-adhesive patch. Earlier nicotine systems commonly used a drug reservoir and rate-controlling membrane. Later products often used multilayer adhesive systems designed to simplify manufacture and reduce patch thickness.

What manufacturing and formulation barriers remain after expiration?

Patent expiration does not remove the technical difficulty of producing a reliable nicotine patch. The main manufacturing barriers include:

Maintaining uniform nicotine concentration across the coated web.
Controlling nicotine loss during drying and storage.
Preventing crystallization or migration into the backing and release liner.
Maintaining adhesive cohesion and skin adhesion.
Controlling nicotine flux across batches.
Managing nicotine’s volatility and chemical compatibility.
Preventing pouch leakage and dose loss.
Meeting residual-solvent, extractables, leachables, and stability requirements.
Demonstrating content uniformity and dose delivery over shelf life.

A formulation that avoids the literal claim architecture may still need to reproduce the reference product’s performance profile. FDA review can therefore remain demanding even after patent expiration.

What litigation and settlement issues affect this patent?

The supplied materials do not establish an active infringement case or settlement involving U.S. Patent 6,165,497. Because the patent expired in 2017, current litigation based solely on these claims would generally be unavailable except for historical claims arising before expiration.

Historical disputes involving nicotine patches could have involved:

Infringement of reservoir or membrane claims.
Validity challenges based on earlier nicotine delivery systems.
Claim construction of "substantially constant" delivery.
The meaning of "useful flux."
Thermodynamic activity and sub-saturation limitations.
Prosecution-history estoppel.
The scope of prior-art disclosures concerning nicotine adhesives and membranes.

Any settlement negotiated during the patent’s term would no longer extend the patent’s statutory exclusionary period. A private agreement could still contain contractual restrictions, but the expired patent itself cannot support a new exclusionary patent claim.

How strong was the patent estate, and what is its current commercial value?

During its term, the patent had meaningful technical scope because its independent claims combined structural elements with measurable delivery performance. Its strongest features were:

A distinct nicotine reservoir.
A separate rate-controlling membrane.
Long-duration delivery.
Defined total delivery rates and flux ranges.
Low thermodynamic activity.
Reservoir-dominant loading.

Its weaknesses included:

Ambiguous quantitative language.
Duplicate claims 6 and 7.
Apparent unit errors in claims 12 and 13.
Dependence on product testing to prove flux and activity.
Potential design-around routes using drug-in-adhesive architecture.
Prior-art exposure from earlier nicotine transdermal systems.

Its current direct commercial value is zero as an exclusionary patent. Its residual value is technological and evidentiary. The patent can help identify the historical design space for nicotine patches, prior-art boundaries, and possible freedom-to-operate issues involving later patents.

Can a company launch a generic nicotine patch without addressing this patent?

Yes, a company can no longer be blocked by U.S. Patent 6,165,497 because the patent has expired. A launch still requires review of:

Active U.S. patents issued after this patent.
FDA pathway and application requirements.
OTC monograph compliance or another applicable regulatory route.
Trademark and trade-dress rights.
Manufacturing controls and quality systems.
Product-specific labeling and nicotine safety requirements.
State and federal controls applicable to nicotine products.

A product using the same reservoir, membrane, adhesive, and flux profile could now practice the expired claims without infringing this patent. The same product may still infringe a later patent if a later patent claims a narrower adhesive, backing, manufacturing process, formulation, or patch configuration.

Key Takeaways

U.S. Patent 6,165,497 covers reservoir-based nicotine transdermal patches with a rate-controlling membrane and adhesive.
The central delivery period is at least eight hours, with some claims requiring at least 16 hours.
Claim 1 requires 250-4,000 μg/hr delivery during a substantial portion of the treatment period.
Claims 8 and 9 impose additional flux and duration limitations.
Claims 2-5 focus on thermodynamic activity, adhesive solubility, and reservoir loading.
Claims 6 and 7 duplicate the 23 μg/cm²/hr limitation.
Claims 12 and 13 contain an apparent mg-versus-μg unit problem.
The patent expired in 2017 and is not a current U.S. exclusivity barrier.
It is not an operative Orange Book obstacle for current nicotine patch entry.
Current freedom-to-operate work should focus on later formulation, adhesive, manufacturing, packaging, and regulatory patents.

FAQs About U.S. Patent 6,165,497 and Nicotine Patch Exclusivity

Does U.S. Patent 6,165,497 cover nicotine gum or nicotine lozenges?

No. The claims are directed to transdermal devices, patches, and methods of applying those patches to skin. They do not cover oral nicotine gum, lozenges, tablets, or inhalation products.

Does the patent cover every nicotine patch?

No. The principal claims require a reservoir, rate-controlling membrane, adhesive or backing structure, and specified delivery performance. A drug-in-adhesive patch may not satisfy all of those limitations.

Can the expired patent still be used to block FDA approval?

No. An expired patent does not provide current patent exclusivity. FDA approval may still require substantial regulatory documentation, but the patent cannot support a current patent-based stay or injunction.

Is a nicotine patch delivering 21 mg over 24 hours within the claimed rate range?

The average total rate would be approximately 875 μg/hr. That falls within claim 1’s 250-4,000 μg/hr total delivery range, but infringement would still require the reservoir, membrane, adhesive, duration, and other limitations.

What patent should be reviewed after U.S. Patent 6,165,497?

The relevant review should cover later U.S. patents directed to drug-in-adhesive nicotine patches, silicone or acrylate adhesive systems, multilayer patch construction, nicotine stabilization, coating and drying processes, packaging, and formulation-specific release control.

References

U.S. Patent No. 6,165,497. (2000). Transdermal nicotine delivery. United States Patent and Trademark Office.
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
U.S. Food and Drug Administration. (n.d.). Nicotine replacement therapy products. https://www.fda.gov/
35 U.S.C. § 154. Patent term. United States Code.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	161734	⤷ Start Trial
Australia	3852189	⤷ Start Trial
Australia	3913695	⤷ Start Trial
Australia	4491193	⤷ Start Trial
Australia	630614	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,165,497

Summary for Patent: 6,165,497